Innate Pharma (NASDAQ:IPHA) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Innate Pharma (NASDAQ:IPHA) in a report published on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock.

A number of other analysts also recently weighed in on IPHA. BTIG Research began coverage on shares of Innate Pharma in a report on Thursday, March 12th. They issued a “buy” rating and a $8.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Innate Pharma in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Innate Pharma Trading Down 2.9%

Shares of NASDAQ IPHA opened at $1.35 on Tuesday. The firm’s fifty day moving average is $1.56 and its two-hundred day moving average is $1.77. Innate Pharma has a 52-week low of $1.17 and a 52-week high of $2.63.

Innate Pharma (NASDAQ:IPHA) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. The business had revenue of $2.41 million for the quarter.

Hedge Funds Weigh In On Innate Pharma

A number of large investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new stake in Innate Pharma in the 4th quarter valued at about $162,000. Millennium Management LLC bought a new position in Innate Pharma in the 4th quarter worth about $36,000. Finally, OLD Mission Capital LLC bought a new position in Innate Pharma in the 4th quarter worth about $50,000. 0.16% of the stock is owned by hedge funds and other institutional investors.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.